Clinical Trial Update: Immunogenicity Safety Study of Wockhardt's Recombinant Insulin Analogue in Type 1 Diabetic Patients [Phase 3]

View source ↗

Summary

A Phase 3 immunogenicity and safety study of Wockhardt's recombinant insulin analogue in Type 1 diabetes has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• Wockhardt's recombinant insulin analogue

Snippet

Sponsor: Wockhardt | Conditions: Type I Diabetes | Phase 3 | Status: WITHDRAWN